Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amicus Therapeutics (FOLD) Change in Acquisitions & Divestments (2016 - 2025)

Amicus Therapeutics (FOLD) has disclosed Change in Acquisitions & Divestments for 16 consecutive years, with $16.9 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Acquisitions & Divestments rose 5.99% year-over-year to $16.9 million, compared with a TTM value of $51.3 million through Dec 2025, down 56.47%, and an annual FY2025 reading of $51.3 million, down 56.47% over the prior year.
  • Change in Acquisitions & Divestments was $16.9 million for Q4 2025 at Amicus Therapeutics, down from $17.3 million in the prior quarter.
  • Across five years, Change in Acquisitions & Divestments topped out at $163.7 million in Q1 2021 and bottomed at $6.2 million in Q1 2025.
  • Average Change in Acquisitions & Divestments over 5 years is $56.3 million, with a median of $54.5 million recorded in 2023.
  • The sharpest move saw Change in Acquisitions & Divestments surged 54.21% in 2021, then tumbled 84.16% in 2025.
  • Year by year, Change in Acquisitions & Divestments stood at $81.7 million in 2021, then fell by 6.97% to $76.0 million in 2022, then plummeted by 78.42% to $16.4 million in 2023, then fell by 3.02% to $15.9 million in 2024, then increased by 5.99% to $16.9 million in 2025.
  • Business Quant data shows Change in Acquisitions & Divestments for FOLD at $16.9 million in Q4 2025, $17.3 million in Q3 2025, and $11.0 million in Q2 2025.